person · Reporting owner

Silverman Joshua

Disclosed activity across 10 companies

Tapewire entity: 23501
SEC CIK: 0001524858

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Fabric.AI, Inc.FABC · Entity 7732	Director · Chief Executive Officer	June 18, 2026	August 14, 2026
NATIONAL HOLDINGS CORPNHLD · Entity 142239	Director	September 12, 2016	September 13, 2016
Neurotrope, Inc.NTRP · Entity 144906	Director	December 01, 2020	December 03, 2020
Petros Pharmaceuticals, Inc.PTPI · Entity 8730	Director	June 05, 2026	June 05, 2026
PharmaCyte Biotech, Inc.PMCB · Entity 8256	Director · CEO and President	January 05, 2026	January 07, 2026
Protagenic Therapeutics, Inc.\newPTIX · Entity 8496	Director	February 21, 2020	February 27, 2020
Q/C TECHNOLOGIES, INC.QCLS · Entity 7735	Director · Executive Chairman	July 10, 2026	October 03, 2026
TAO Synergies Inc.TAOX · Entity 7482	Director · Executive Chairman	May 18, 2026	May 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Fabric.AI, Inc.

Report date June 18, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	280,757	Ending reported balance After 2026-06-30 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-06-18 · Grant · Acquired 358,565 · Balance 370,397 F1: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026. Row 2 · 2026-06-18 · Tax withholding · Disposed 44,820 · Balance 325,577 Row 3 · 2026-06-30 · Tax withholding · Disposed 44,820 · Balance 280,757

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026.

NATIONAL HOLDINGS CORP

Report date September 12, 2016 · Filed September 13, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.02 per shareSEC Table I · non-derivative	IndirectSee Footnote	414,323	Reported balance After 2016-09-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2016-09-12 · Other · Acquired 414,323 · Balance 414,323 F1: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Neurotrope, Inc.

Report date December 01, 2020 · Filed December 03, 2020

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-12-01 transaction · row 1 1 source row Row 1 · 2020-12-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.20	Direct	Reported balance After 2020-12-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-01 · Disposition to issuer · Disposed 9,375 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56	Direct	Reported balance After 2020-12-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-01 · Disposition to issuer · Disposed 124,275 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10	Direct	Reported balance After 2020-12-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.62	Direct	Reported balance After 2020-12-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-12-01 · Disposition to issuer · Disposed 167,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91	Direct	Reported balance After 2020-12-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93	Direct	Reported balance After 2020-12-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-12-01 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06	Direct	Reported balance After 2020-12-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82	Direct	Reported balance After 2020-12-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97	Direct	Reported balance After 2020-12-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-12-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.

F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.

Petros Pharmaceuticals, Inc.

Report date June 05, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,790,450	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,375,000 · Balance 8,790,450 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

PharmaCyte Biotech, Inc.

Report date January 05, 2026 · Filed January 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	416,250	Ending reported balance After 2026-01-07 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-01-05 · Purchase · Acquired 30,000 · Balance 346,250 Row 2 · 2026-01-06 · Purchase · Acquired 30,000 · Balance 376,250 Row 3 · 2026-01-07 · Purchase · Acquired 40,000 · Balance 416,250
Common StockSEC Table I · non-derivative	IndirectJNS Holdings Group LLC	50,000	Reported balance Holding disclosure · report date 2026-01-05 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 50,000

Protagenic Therapeutics, Inc.\new

Report date February 21, 2020 · Filed February 27, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
PTIX Common stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2030-02-21	Direct	120,000	Reported balance After 2020-02-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-21 · Grant · Acquired 120,000 · Balance 120,000

Q/C TECHNOLOGIES, INC.

Report date July 10, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	210,845	Ending reported balance After 2026-10-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-07-10 · Grant · Acquired 16,620 · Balance 133,455 F1: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement. Row 2 · 2026-10-01 · Grant · Acquired 77,390 · Balance 210,845 F2: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

F2: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

TAO Synergies Inc.

Report date May 18, 2026 · Filed May 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18	Direct	200,000	Reported balance After 2026-05-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-18 · Grant · Acquired 200,000 · Balance 200,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

FEMASYS INC

Report date March 17, 2026 · Filed March 18, 2026

Section 16 reporting ended · disclosed 2026-03-18. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Marker Therapeutics, Inc.

Report date October 16, 2018 · Filed October 17, 2018

Section 16 reporting ended · disclosed 2018-10-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,221	Reported balance After 2018-10-16 transaction · row 1 1 source row Row 1 · 2018-10-16 · Grant · Acquired 4,106 · Balance 17,221 F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.
Common StockSEC Table I · non-derivative	IndirectBy JNS Holdings Group LLC	153,333	Reported balance Holding disclosure · report date 2018-10-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 153,333

Filing footnotes · ownership attribution and instrument terms

F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 11, 2022 Filed Nov 4, 2022 01:04 UTC	Fabric.AI, Inc. AYRO · Entity 7732	SaleCommon Stock	12,855	$0.82	$10,541.10	Disclosure SEC source: 0001493152-22-030401 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,169 F1 · shares: Represents a broker-assisted sale of shares to pay taxes upon the vesting of an award. Read SEC document
April 07, 2022 Filed Apr 11, 2022 21:01 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantRestricted Stock Units · Derivative	67,227	$0.00	$0.00	Disclosure SEC source: 0001104659-22-044715 · tm2212468d3_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,227 Underlying: Common Stock · 67,227 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date. F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date. Read SEC document
April 05, 2022 Filed Apr 6, 2022 21:01 UTC	TAO Synergies Inc. SNPX · Entity 7482	GrantStock Option (Right to Buy) · Derivative	1,500	$0.00 Strike: $7.41	$0.00	Disclosure SEC source: 0001104659-22-043275 · tm2212026-3_4seq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock, par value $0.0001 per share · 1,500 shares Expires 2032-04-05 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022. Read SEC document
April 05, 2022 Filed Jun 23, 2022 22:01 UTC Amendment	TAO Synergies Inc. SNPX · Entity 7482	OtherStock Option (Right to Buy) · Derivative	0	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-073972 · tm2219110-3_4aseq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares Expires not disclosed F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Silverman, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. Read SEC document
February 01, 2022 Filed Feb 3, 2022 22:08 UTC	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	114,729	$0.00	$0.00	Disclosure SEC source: 0001493152-22-003115 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,024 F1 · shares: Shares will vest in four equal installments on each quarterly anniversary of the Grant Date, provided that Mr. Silverman is employed by or providing services to the Company through the applicable vesting date and subject to the terms and conditions of the AYRO, Inc. Long-Term Incentive Plan. Read SEC document
December 22, 2021 Filed Jan 7, 2022 21:45 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantRestricted Stock Units · Derivative	25,156	$0.00	$0.00	Disclosure SEC source: 0001104659-22-002306 · tm222320d3_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,156 Underlying: Common Stock · 25,156 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date Read SEC document
November 26, 2021 Filed Nov 29, 2021 17:46 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	PurchaseCommon Stock	5,000	$7.55	$37,771.50	Disclosure SEC source: 0001493152-21-029973 · ownership.xml · nonDerivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,775 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.70, inclusive. Read SEC document
November 24, 2021 Filed Nov 29, 2021 17:46 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	PurchaseCommon Stock	3,266	$7.09	$23,168.02	Disclosure SEC source: 0001493152-21-029973 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,775 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.17, inclusive. Read SEC document
November 24, 2021 Filed Nov 29, 2021 17:46 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	PurchaseCommon Stock	6,734	$6.30	$42,418.14	Disclosure SEC source: 0001493152-21-029973 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.97 to $6.96, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4. Read SEC document
October 14, 2021 Filed Oct 15, 2021 21:20 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	GrantRestricted Stock Units · Derivative	600,000	$0.00	$0.00	Disclosure SEC source: 0001493152-21-025602 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. Read SEC document
July 13, 2021 Filed Jul 15, 2021 22:04 UTC	TAO Synergies Inc. SNPX · Entity 7482	GrantCommon Stock, par value $0.0001 per share	90,000	$0.00	$0.00	Disclosure SEC source: 0001104659-21-092712 · tm2122331-1_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 F1 · balance_after: Includes 90,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date. Read SEC document
July 13, 2021 Filed Dec 2, 2022 00:52 UTC Amendment	TAO Synergies Inc. SNPX · Entity 7482	GrantCommon Stock, par value $0.0001 per share	42,250	$0.00	$0.00	Disclosure SEC source: 0001104659-22-123805 · tm2231816-6_4aseq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,250 F1 · shares: This filing amends the Form 4, filed on July 15, 2021 by Mr. Silverman to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. Read SEC document
June 14, 2021 Filed Jun 16, 2021 17:00 UTC	TAO Synergies Inc. SNPX · Entity 7482	PurchaseCommon Stock, par value $0.0001 per share	10,000	$8.30	$83,000.00	Disclosure SEC source: 0001104659-21-081897 · tm2119874d1_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.75 to $8.49, inclusive. The reporting person undertakes to provide to Synaptogenix, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
June 04, 2021 Filed Jun 8, 2021 20:00 UTC	Fabric.AI, Inc. AYRO · Entity 7732	SaleCommon Stock	39,008	$5.17	$201,686.96	Disclosure SEC source: 0001493152-21-013812 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,295 F1 · shares: Represents a broker-assisted sale of shares to satisfy tax withholding obligations upon the vesting of an award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.17 to $5.2183, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
April 16, 2021 Filed Apr 21, 2021 01:35 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	Exercise / conversionRestricted Stock Units · Derivative	109,500	$0.00	$0.00	Disclosure SEC source: 0001493152-21-009294 · ownership.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F3 · derivative.exercise_date: On September 11, 2020, the reporting person was granted 109,500 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control. F3 · derivative.expiration_date: On September 11, 2020, the reporting person was granted 109,500 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control. Read SEC document
April 16, 2021 Filed Apr 21, 2021 01:35 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	Tax withholdingCommon Stock	38,325	$4.94	$189,325.50	Disclosure SEC source: 0001493152-21-009294 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,175 F2 · shares: Represents 38,325 shares of RSUs withheld to pay the reporting person's tax withholding obligations incurred in connection with the vesting of 109,500 shares of RSUs on April 16, 2021. Read SEC document
April 16, 2021 Filed Apr 21, 2021 01:35 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	Exercise / conversionCommon Stock	109,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-21-009294 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). Read SEC document
April 08, 2021 Filed Apr 9, 2021 20:15 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $3.18	$0.00	Disclosure SEC source: 0001567619-21-007861 · doc1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document
February 24, 2021 Filed Feb 26, 2021 22:30 UTC	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	42,000	$0.00	$0.00	Disclosure SEC source: 0001493152-21-004994 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,303 F1 · shares: Represents restricted shares of common stock granted to the reporting person. 50% of such shares vest on June 30, 2021, and the remaining shares vest in two equal quarterly installments over the following six months. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	20,000	Not disclosed Strike: $4.86	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 10 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-11-24 F19 · price: Received in connection with the Transactions in exchange for a stock option to acquire 100,000 shares of Neurotrope common stock for $0.972 per share. F18 · derivative.exercise_date: All shares subject to the option vested in connection with the Transactions. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	2,000	Not disclosed Strike: $4.10	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 9 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2030-03-20 F17 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $0.82 per share. F16 · derivative.exercise_date: All shares subject to the option shall vest on March 20, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	2,000	Not disclosed Strike: $20.30	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 8 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2029-03-15 F15 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $4.06 per share. F14 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $19.65	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 7 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-22 F13 · price: Received in connection with the Transactions in exchange for a stock option to acquire 150,000 shares of Neurotrope common stock for $3.93 per share. F12 · derivative.exercise_date: 28,125 shares subject to the option are vested as of the date hereof and the remaining shares subject to the option shall vest quarterly through January 22, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	2,000	Not disclosed Strike: $44.56	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 6 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2028-03-13 F11 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $8.912 per share. F10 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	33,400	Not disclosed Strike: $98.10	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 5 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,400 Underlying: Common Stock · 33,400 shares Expires 2027-04-11 F9 · price: Received in connection with the Transactions in exchange for a stock option to acquire 167,000 shares of Neurotrope common stock for $19.62 per share. F8 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	2,000	Not disclosed Strike: $95.50	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 4 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-03-17 F7 · price: Received in connection with the Transactions in exchange for a stock option to acquire 10,000 shares of Neurotrope common stock for $19.10 per share. F6 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	24,855	Not disclosed Strike: $52.80	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,855 Underlying: Common Stock · 24,855 shares Expires 2026-11-22 F5 · price: Received in connection with the Transactions in exchange for a stock option to acquire 124,275 shares of Neurotrope common stock for $10.56 per share. F4 · derivative.exercise_date: All shares subject to the option are vested as of the date hereof. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantEmployee Stock Option (right to buy) · Derivative	1,875	Not disclosed Strike: $96.00	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2026-08-04 F3 · price: Received in connection with the Transactions in exchange for a stock option to acquire 9,375 shares of Neurotrope common stock for $19.20 per share. F2 · derivative.exercise_date: 1,623 shares subject to the option are vested as of the date hereof and the remaining shares subject to the option shall vest daily through August 4, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 01, 2020 Filed Dec 3, 2020 02:10 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantCommon Stock, par value $0.0001 per share	20,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-131729 · tm2037431-3_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: Received in exchange for 100,000 shares of Neurotrope, Inc. ("Neurotrope") common stock in connection with the transactions (the "Transactions") contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the "the Original Merger Agreement"), as amended by the First Amendment to the Original Merger Agreement (the "First Amendment") , dated as of July 23, 2020 and the Second Amendment to the Original Merger Agreement, dated as of September 30, 2020 (the "Second Amendment" and, together with the Original Merger Agreement and the First Amendment, the "Merger Agreement") by and among Petros Pharmaceuticals, Inc. (the "Company"), Neurotrope, PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company ("Merger Sub 1"), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company ("Merger Sub 2"), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	100,000	Not disclosed Strike: $0.97	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 10 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $0.82	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 9 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $4.06	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 8 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	150,000	Not disclosed Strike: $3.93	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 7 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $8.91	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 6 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	167,000	Not disclosed Strike: $19.62	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 5 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $19.10	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 4 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	124,275	Not disclosed Strike: $10.56	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,275 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	9,375	Not disclosed Strike: $19.20	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:40 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerCommon Stock	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-132149 · tm2037705d2_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. Read SEC document
November 24, 2020 Filed Nov 27, 2020 17:07 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	100,000	$0.00 Strike: $0.97	$0.00	Disclosure SEC source: 0001104659-20-130071 · tm2037145d2_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). F2 · derivative.expiration_date: In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. Read SEC document
October 16, 2020 Filed Oct 20, 2020 09:00 UTC	Neurotrope, Inc. NTRP · Entity 144906	PurchaseCommon Stock	50,000	$1.09	$54,445.00	Disclosure SEC source: 0001104659-20-116286 · tm2033760d2_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.10, inclusive. The reporting person undertakes to provide to Neurotrope, Inc., any security holder of Neurotrope, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
October 15, 2020 Filed Oct 19, 2020 09:00 UTC	Neurotrope, Inc. NTRP · Entity 144906	PurchaseCommon Stock	50,000	$1.07	$53,315.00	Disclosure SEC source: 0001104659-20-115850 · tm2033760d1_4.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive. The reporting person undertakes to provide to Neurotrope, Inc., any security holder of Neurotrope, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
September 29, 2020 Filed Oct 2, 2020 00:01 UTC	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	122,547	$0.00	$0.00	Disclosure SEC source: 0001493152-20-018747 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,303 F1 · shares: 5,668 shares of this grant vested in full on the date of grant, and the remaining 116,879 shares of this grant will vest in full on December 31, 2020, provided that the reporting person has continuously provided services to the issuer through that date. Read SEC document
September 29, 2020 Filed Dec 28, 2020 18:28 UTC Amendment	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	122,547	$0.00	$0.00	Disclosure SEC source: 0001493152-20-024330 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,303 F1 · shares: The reporting person's original Form 4 indicated that 5,668 shares of this grant vested in full on the date of grant, and the remaining 116,879 shares of this grant would vest in full on December 31, 2020. On December 24, 2020, the issuer and the reporting person mutually agreed to amend the vesting terms of the remaining 116,879 shares of this grant, with such shares now vesting in full on May 28, 2021, provided that the reporting person has remained employed by or is providing services to the issuer through the applicable vesting date. Read SEC document
September 11, 2020 Filed Sep 11, 2020 22:27 UTC	Q/C TECHNOLOGIES, INC. AKER · Entity 7735	GrantRestricted Stock Unit · Derivative	219,000	$0.00	$0.00	Disclosure SEC source: 0001493152-20-017672 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,000 Underlying: Common Stock · 219,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause. F2 · derivative.expiration_date: Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause. Read SEC document
May 28, 2020 Filed Jun 2, 2020 00:26 UTC	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	9,756	$0.00	$0.00	Disclosure SEC source: 0001493152-20-010333 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,756 F1 · shares: Such numbers have been revised to reflect a 1-for-10 reverse stock split of the Issuer's common stock effected on May 28, 2020 and a 1-for-1 stock dividend effected thereafter on May 28, 2020. F2 · shares: Represents shares of restricted stock granted to the reporting person on May 28, 2020. F1 · balance_after: Such numbers have been revised to reflect a 1-for-10 reverse stock split of the Issuer's common stock effected on May 28, 2020 and a 1-for-1 stock dividend effected thereafter on May 28, 2020. Read SEC document
March 20, 2020 Filed Mar 24, 2020 18:02 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $0.82	$0.00	Disclosure SEC source: 0001104659-20-037867 · tm2013506d5_4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-20 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document
February 21, 2020 Filed Feb 27, 2020 01:26 UTC	Protagenic Therapeutics, Inc.\new PTIX · Entity 8496	GrantPTIX Common stock Options · Derivative	120,000	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0001493152-20-003039 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: PTIX Common Stock, Par Value $0.0001 · 120,000 shares Expires 2030-02-21 Read SEC document
January 01, 2020 Filed Jan 4, 2020 00:07 UTC	Q/C TECHNOLOGIES, INC. AKER · Entity 7735	Exercise / conversionRestricted Stock Units · Derivative	5,201	$0.00	$0.00	Disclosure SEC source: 0001493152-20-000164 · ownership.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). F2 · derivative.exercise_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020. F2 · derivative.expiration_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020. Read SEC document
January 01, 2020 Filed Jan 4, 2020 00:07 UTC	Q/C TECHNOLOGIES, INC. AKER · Entity 7735	Exercise / conversionCommon Stock	5,201	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-20-000164 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.